Please upgrade your browser.
AGS-003 is a new type of personalized immunotherapy that is being evaluated in a phase 3 clinical study called ADAPT for the treatment of advanced kidney cancer.
Learn how a study using an investigational drug (BNC105P) can be a treatment option for you.
The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma
Eighty-one patients with 216 BMs were identified. Thirty-seven patients had BM at diagnosis and the remaining 44 were found to have BM at a later point. Forty-one patients never received a TKI and the remaining 40 received TKIs.
Greetings of the holiday season from everyone at the Kidney Cancer Association
Before the Affordable Care Act, doctors in the US were on the side of patients, but this does not appear to be true in the UK.
Can diet help to stave off metastatic disease?
Few types of cancer have had their treatment evolve as rapidly as metastatic renal cell carcinoma (mRCC).
The standard of care for small renal masses has shifted from radical nephrectomy to a strategy to preserve the volume of working kidney as well as the quality of life of the patient. Depending on the size of the tumor and the tissue type (as determined by biopsy), small masses might be watched, or a partial nephrectomy performed to remove the tumor and save as much kidney as possible.
Conquer Cancer Foundation of ASCO Honors Researchers for Work in Measuring and Improving the Quality of Cancer Care
Merck is testing ridaforolimus in other cancer types including kidney cancer.
|Powered by NeonCRM|